BioNTech Soars 10.44% on Strategic Partnership, Earnings
BioNTech's stock surged by 10.44% in pre-market trading on June 2, 2025, marking a significant rise for the biotechnology company.
Morgan Stanley recently adjusted its target price for BioNTechBNTX--, lowering it from $140.00 to $132.00 while maintaining an "overweight" rating for the company. This adjustment reflects the firm's ongoing evaluation of BioNTech's financial performance and market prospects.
BioNTech and Bristol Myers Squibb (BMS) have announced a strategic partnership for the joint development and manufacturing of their products. The collaboration will see both companies sharing costs and profits on a 50:50 basis, subject to certain exceptions. This partnership is expected to enhance BioNTech's operational efficiency and market reach.
In the first quarter of 2025, BioNTech reported a loss but maintained its financial guidance for the year. The company also welcomed Ramón Zapata-Gomez as its new Chief Financial Officer, a move aimed at strengthening its financial management and strategic planning.
Obtén información sobre los actores clave en el mercado de valores de los Estados Unidos antes de que comience la sesión de negociación.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
Comments
No comments yet